Key result
Micro- and nanoplastic detection rates and peripheral arterial concentrations were significantly higher in STEMI than in chronic coronary syndromes or controls.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Regarding reverse causation, this is where the heart attack results in elevated microplastics. This isn’t implausible; people who present to hospital with a suspected heart attack typically receive intravenous infusions as part of their management. It is known that intravenous infusions shed microplastics into the blood. Given that microplastics do not usually remain in the blood stream for long, this seems a credible mechanism and is not discussed by the authors.”
“However, the study remains relatively small (61 patients) and cross-sectional, so it cannot determine whether microplastics contribute to the development of acute coronary events or whether they accumulate as a consequence of the disease process itself.”
“Heart attack patients had significantly higher levels of microplastics than controls or other coronary disease patients. The fact that microplastics are present at higher levels in heart attack patients does not prove that they are the root cause of the disease. It might be that exposure to something else is associated with microplastics, but the ‘something else’ has not been measured in the study.”
This commentary clarifies that higher systemic micro- and nanoplastic burdens in peripheral blood of STEMI patients suggest a dual mechanism of antecedent systemic exposure predisposing to atherothrombosis alongside post-thrombotic local enrichment.
This commentary refers to ‘Micro- and nano-plastics in the coronary circulation and air pollution exposure in ischaemic heart disease presentation’, by P. Paolisso et al., https://doi.org/10.1093/eurheartj/ehag447 and the discussion piece ‘Coronary micro- and nanoplastics in ST-segment elevation myocardial infarction: antecedent exposure or post-thrombotic enrichment’, by J. Qin et al., https://doi.org/10.1093/eurheartj/ehag800. We thank Qin et al.1 for their thoughtful commentary on our study of micro- and nanoplastics (MNPs) in the coronary circulation across the spectrum of coronary artery disease. The authors raise two principal points: whether the proximal-to-peripheral gradient observed in ST-segment elevation myocardial infarction (STEMI) reflects antecedent exposure or post-thrombotic enrichment and whether smoking confounds the association between MNPs and acute coronary thrombosis. We welcome the opportunity to clarify these issues. We agree that our cross-sectional, single-timepoint sampling design cannot definitively separate focal accumulation preceding plaque rupture from secondary enrichment occurring after thrombotic occlusion. We emphasize that this local mechanism cannot alone account for our findings. Indeed, our most robust finding was not the concentration gradient itself but the markedly different rate of patients with detectable MNPs across the three groups, highest in STEMI, intermediate in chronic coronary syndromes, and lowest in controls, a binary difference in presence vs absence that local stasis or thrombus-related sequestration at a single occlusion site does not readily explain. Moreover, we deliberately used peripheral arterial blood, sampled at the vascular sheath and remote from the culprit lesion, as the reference compartment for this comparison to avoid confounding from local thrombus formation and flow disruption at the site of coronary occlusion. Peripheral arterial MNP concentrations were also significantly higher in STEMI than in chronic coronary syndromes or controls, a systemic difference that stasis or thrombus-related sequestration at the occlusion site cannot explain.2 We therefore view antecedent exposure and post-thrombotic local enrichment not as competing explanations but as plausibly coexisting phenomena: a higher systemic MNP burden predisposing to atherothrombotic events, superimposed on focal concentration once coronary flow is disrupted. The design proposed by the authors—comparing polymer burden and composition across peripheral blood, upstream and downstream coronary blood, aspirated thrombus, and plaque tissue from the same patient—is precisely the direction we are now pursuing, building on prior work demonstrating MNPs within coronary and peripheral thrombi and within atherosclerotic plaque itself.3–6
No takes yet. Share an insight, caveat, or question.
Marfella et al. (2026) conducted a letter in ST-segment elevation myocardial infarction and chronic coronary syndromes. Micro- and nanoplastics (MNPs) in the coronary and peripheral arterial circulation vs. Chronic coronary syndromes and controls was evaluated on Detectable MNPs and MNP concentrations in peripheral and coronary arterial blood. Micro- and nanoplastic detection rates and peripheral arterial concentrations were significantly higher in STEMI than in chronic coronary syndromes or controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: